Skip navigation
Inside. Outside. On His Side.


  I Do Not Reside in the U.S. GO

 
Only CUBICIN is indicated for S. aureus bacteremia
Clinicians have treated more than 500,000 patients* with CUBICIN, inside and out
Discharge patients on CUBICIN, the only once daily option for MRSA skin and bacteremia
  *Estimated number of patients treated based on sales through March 2008.
Web Conferences
These online forums feature thought leaders, offering physicians expert insight and strategies for managing S. aureus bacteremia and complicated skin infections. Click to access.

ACTIV[tm]
Cubist Pharmaceuticals has established ACTIV (Assessing CUBICIN Therapy in Vitro) to monitor susceptibility of CUBICIN (daptomycin for injection) to certain gram-positive organisms. Click to access.